Recombinant human serum albumin biosimilar - Protgen
Latest Information Update: 20 Aug 2024
At a glance
- Originator Protgen
- Class Acute-phase proteins; Albumins; Plasma expanders; Recombinant fusion proteins; Recombinant proteins
- Mechanism of Action Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Liver cirrhosis
- No development reported Ascites
Most Recent Events
- 13 Aug 2024 Protgen plans a phase II/III trial of recombinant human serum albumin biosimilar for Cirrhotic ascites in China in August 2024 (IV) (NCT06553456)
- 28 May 2024 No recent reports of development identified for phase-I development in Ascites in China (IV, Injection)
- 14 Oct 2021 Phase-I clinical trials in Liver cirrhosis in China (IV) (NCT05249374)